JP2017519501A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519501A5
JP2017519501A5 JP2016573833A JP2016573833A JP2017519501A5 JP 2017519501 A5 JP2017519501 A5 JP 2017519501A5 JP 2016573833 A JP2016573833 A JP 2016573833A JP 2016573833 A JP2016573833 A JP 2016573833A JP 2017519501 A5 JP2017519501 A5 JP 2017519501A5
Authority
JP
Japan
Prior art keywords
antibody
axl
domain
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573833A
Other languages
English (en)
Japanese (ja)
Other versions
JP6787795B2 (ja
JP2017519501A (ja
Filing date
Publication date
Priority claimed from GBGB1410826.0A external-priority patent/GB201410826D0/en
Application filed filed Critical
Publication of JP2017519501A publication Critical patent/JP2017519501A/ja
Publication of JP2017519501A5 publication Critical patent/JP2017519501A5/ja
Application granted granted Critical
Publication of JP6787795B2 publication Critical patent/JP6787795B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573833A 2014-06-18 2015-06-18 抗Ａｘｌ抗体 Expired - Fee Related JP6787795B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1410826.0 2014-06-18
GBGB1410826.0A GB201410826D0 (en) 2014-06-18 2014-06-18 Anti-axl antibodies
PCT/EP2015/063700 WO2015193428A1 (en) 2014-06-18 2015-06-18 Anti-axl antibodies

Publications (3)

Publication Number Publication Date
JP2017519501A JP2017519501A (ja) 2017-07-20
JP2017519501A5 true JP2017519501A5 (enExample) 2018-05-10
JP6787795B2 JP6787795B2 (ja) 2020-11-18

Family

ID=51266761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573833A Expired - Fee Related JP6787795B2 (ja) 2014-06-18 2015-06-18 抗Ａｘｌ抗体

Country Status (15)

Country Link
US (3) US9975954B2 (enExample)
EP (1) EP3157559B1 (enExample)
JP (1) JP6787795B2 (enExample)
KR (1) KR102453226B1 (enExample)
CN (2) CN106573979B (enExample)
AU (1) AU2015276153B2 (enExample)
CA (1) CA2952296A1 (enExample)
DK (1) DK3157559T3 (enExample)
GB (1) GB201410826D0 (enExample)
HR (1) HRP20201091T1 (enExample)
HU (1) HUE049755T2 (enExample)
LT (1) LT3157559T (enExample)
MX (1) MX388222B (enExample)
SI (1) SI3157559T1 (enExample)
WO (1) WO2015193428A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
EP3229836B1 (en) * 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016097370A2 (en) 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
GB201506411D0 (en) * 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
RS61795B1 (sr) * 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
US20210215697A1 (en) 2018-05-14 2021-07-15 Bergenbio Asa Serum Biomarkers
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
EP3946453A4 (en) * 2019-03-29 2022-12-07 Celldex Therapeutics, Inc. ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN113045664B (zh) * 2019-11-28 2023-05-12 尚健单抗（北京）生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
WO2021154156A1 (en) * 2020-01-31 2021-08-05 Agency For Science, Technology And Research Anti-axl antibody and uses thereof
US11807688B2 (en) * 2020-02-28 2023-11-07 Les Laboratoires Servier Anti-AXL antibodies and compositions
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
WO2022164288A1 (ko) 2021-01-29 2022-08-04 한국과학기술원 비염증성 식세포작용 유도 활성을 갖는 융합분자
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
IL289525B2 (en) * 2021-12-30 2023-03-01 B G Negev Technologies And Applications Ltd At Ben Gurion Univ Conjugated antibodies for cancer treatment
CN116348497B (zh) * 2023-01-05 2023-11-17 浙江时迈药业有限公司 针对axl的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
BRPI0820073A2 (pt) 2007-11-12 2015-06-23 U3 Pharma Gmbh Anticorpos anti-axl
CN101918452A (zh) 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用
EP2198884A1 (en) * 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
TW201106972A (en) * 2009-07-27 2011-03-01 Genentech Inc Combination treatments
CN103080136B (zh) * 2010-06-18 2015-08-12 霍夫曼-拉罗奇有限公司 抗Axl抗体及使用方法
AU2012273955A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
WO2012175691A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
WO2016097370A2 (en) * 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
GB201506411D0 (en) * 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2018193102A1 (en) * 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate

Similar Documents

Publication Publication Date Title
JP2017526339A5 (enExample)
JP2018506961A5 (enExample)
JP2021008487A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
CN102741282B (zh) 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途
JP2022548066A5 (enExample)
JP2017535257A5 (enExample)
JP2024544520A5 (enExample)
IL276950B1 (en) Anti-cd73 antibodies and uses thereof
AU2019303030A1 (en) Anti-mesothelin antibodies
JP2020534830A5 (enExample)
JP6608698B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP2017529838A5 (enExample)
JP2020537520A5 (enExample)
JP2013527761A5 (enExample)
AU2020212534B2 (en) High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2021501744A5 (enExample)
JP7860899B2 (ja) ＴＲＢＣβ抗体コンジュゲート
HRP20180352T1 (hr) Protutijela anti-fcrh5
JP2023540526A5 (enExample)
JP2022533538A5 (enExample)
KR20230016186A (ko) 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
JP2018500014A5 (enExample)
JP2017530692A5 (enExample)
JP2016536342A5 (enExample)
JP2019534705A5 (enExample)